Age [years] | ||
Mean (SD) | 76.9 (4.53) | |
Range | 70–88 | |
Charlson Comorbidity Indexa | ||
Mean (SD) | 1.05 (1.237) | |
Range | 0–7 | |
Creatinine Clearance (Cockcroft-Gault) [mL/min] | ||
Mean (SD) | 67.2 (22.89) | |
Range | 10–131 | |
n | % | |
Sex | ||
Female | 68 | 50.0 |
Male | 68 | 50.0 |
ECOG performance status | ||
Fully active (0) | 45 | 33.1 |
Capable of all self-care (1–2) | 74 | 54.4 |
Limited or no self-care (3–4) | 17 | 12.5 |
Tumor entityb | ||
Respiratory | 34 | 25.0 |
Hematological | 57 | 41.9 |
Gynecological | 5 | 3.7 |
Genitourinary | 3 | 2.2 |
Unknown primary | 4 | 2.9 |
Musculoskeletal | 1 | 0.7 |
Digestive/gastrointestinal | 16 | 11.8 |
Breast | 13 | 9.6 |
Others | 3 | 2.1 |
Relapse | ||
No | 118 | 86.8 |
Yes | 18 | 13.2 |
Cancer stage | ||
I | 7 | 5.1 |
II | 11 | 8.1 |
III | 31 | 22.8 |
IV | 68 | 50.0 |
Missing | 19 | 14.0 |
Treatment type | ||
Chemotherapy | 81 | 59.6 |
Targeted or immunotherapy | 9 | 6.6 |
Combined chemotherapy and targeted or immunotherapy | 46 | 33.8 |